SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals informs about press release

17 Apr 2018 Evaluate

Glenmark Pharmaceuticals has informed about press release titled ‘Glenmark Pharmaceuticals Announces Initiation of a Phase 2b Trial of GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis’.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharma. Share Price

2287.55 22.30 (0.98%)
10-Jul-2026 11:44 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1936.90
Dr. Reddys Labs. 1240.30
Cipla 1450.05
Zydus Lifesciences 1152.85
Lupin 2501.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: